Literature DB >> 30807892

Chronic kidney disease in adults with schizophrenia: A nationwide population-based study.

Dana Tzur Bitan1, Israel Krieger2, Anat Berkovitch3, Doron Comaneshter4, Arnon Cohen5.   

Abstract

OBJECTIVE: Several studies have recently reported an association between chronic kidney disease (CKD) and schizophrenia, yet this association has not been sufficiently established. The aim of this study was to examine the association between schizophrenia and CKD in a large dataset, as well as to assess the level of accessibility of these patients to common treatments for CKD.
METHOD: Patients diagnosed with schizophrenia (n = 27,516) and an equal number of age and sex frequency-matched controls were included in this nationwide population-based study. Logistic regressions and ROC curves were employed to assess the association between schizophrenia and CKD and the level of fit of the models.
RESULTS: Schizophrenia was associated with CKD, after controlling for demographic, behavioral, and medical risk factors (OR = 1.62, CI 1.45-1.82, p < .0001). After adjusting for demographic and behavioral risk factors, CKD patients without schizophrenia were more likely to receive dialysis (OR = 1.70, 95% CI 1.18-2.44, p < .01) and kidney transplantation (OR = 5.43, 95% CI 2.84-10.38, p < .001) as compared to CKD patients with schizophrenia.
CONCLUSION: As CKD affects survival, quality of life, and medical and familial burden, additional thought should be given to detection of CKD, as well as to accessibility to treatment, among patients with schizophrenia.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Accessibility; Cohort design; Dialysis; Kidney transplantation; Population-based study

Year:  2019        PMID: 30807892     DOI: 10.1016/j.genhosppsych.2019.01.007

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  4 in total

1.  COVID-19 Booster Vaccination Among Individuals With Schizophrenia in Israel.

Authors:  Dana Tzur Bitan; Khalaf Kridin; Noga Givon-Lavi; Israel Krieger; Ehud Kaliner; Arnon Dov Cohen; Orly Weinstein
Journal:  JAMA Psychiatry       Date:  2022-05-01       Impact factor: 25.911

2.  Machine learning analysis of exome trios to contrast the genomic architecture of autism and schizophrenia.

Authors:  Sameer Sardaar; Bill Qi; Alexandre Dionne-Laporte; Guy A Rouleau; Reihaneh Rabbany; Yannis J Trakadis
Journal:  BMC Psychiatry       Date:  2020-02-28       Impact factor: 3.630

3.  Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice.

Authors:  Geng-Ruei Chang; Po-Hsun Hou; Wei-Cheng Yang; Chao-Min Wang; Pei-Shan Fan; Huei-Jyuan Liao; To-Pang Chen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-16

4.  Abnormal corneal nerve morphology and brain volume in patients with schizophrenia.

Authors:  Georgios Ponirakis; Reem Ghandi; Amani Ahmed; Hoda Gad; Ioannis N Petropoulos; Adnan Khan; Ahmed Elsotouhy; Surjith Vattoth; Mahmoud K M Alshawwaf; Mohamed Adil Shah Khoodoruth; Marwan Ramadan; Anjushri Bhagat; James Currie; Ziyad Mahfoud; Hanadi Al Hamad; Ahmed Own; Peter M Haddad; Majid Alabdulla; Rayaz A Malik; Peter W Woodruff
Journal:  Sci Rep       Date:  2022-02-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.